Anvisa recommends suspending the vaccination of pregnant women with AstraZeneca and Janssen – Prime Time Zone

5

Agency recommends restriction of vaccines that use adenoviral vectors, but reinforces that the benefits of immunizing agents outweigh the risks

EFE / EPA / JUNG YEON-JE / ArchiveOxford/AstraZeneca vaccine

The National Health Surveillance Agency (Anvisa) proposed to suspend the vaccination of pregnant women with the immunizing agents of AstraZeneca and Janssen, who use an adenoviral vector. The agency warned of the need to institute measures for the early identification of suspected cases of thrombocytopenia who received this type of vaccine. The risk, however, is low. Between 0.1% to 0.5% of the total vaccinated had the disease. “The most frequent signs and symptoms associated with TTS are shortness of breath, chest pain, leg swelling, persistent abdominal pain and neurological symptoms such as severe and persistent headaches (which do not give in to the use of painkillers) or blurred vision. After using vaccines against Covid-19, anyone who presents the symptoms mentioned above should seek immediate medical care”, says the agency. Anvisa had already proposed the suspension of the application of AstraZeneca for pregnant women in May. However, on Friday, 2nd, it released a statement extending the restriction for the vaccine of Janssen. The agency also noted that the benefits of vaccines outweigh the risks associated with coronavirus infection. “Anvisa reinforces the favorable benefit-risk ratio of vaccines against Covid-19 authorized for use in the country, being essential the continuity of immunization of the population.”